Bavarian Nordic's PROSTVAC® update & reception June 4, 2012 in Chicago
Thursday, May 24, 2012 at 4:46PM
DDE Editor in Conferences

Bavarian Nordic's PROSTVAC® update & reception will be held in Chicago on Monday, June 4, 2012.


PROSTVAC® is a therapeutic vaccine currently enrolling in a pivotal Phase 3 trial (PROSPECT) of 1,200 patients with asymptomatic or minimally symptomatic castration-resistant prostate cancer that was initiated in November 2011 and is expected to form the basis for approval of the vaccine for this patient population. 

Pre-registration for the June 4 event is required and attendance is limited, so please click "Register Now!" to RSVP today.

Speakers at the event include:
  • Dr. James L. Gulley (NCI)
  • Dr. Philip W. Kantoff (Dana-Farber)
  • Anders Hedegaard (Bavarian Nordic)
  • Dr. Reiner Laus (Bavarian Nordic)
Contacts:
Mettes Buhls 
Bavarian Nordic 
mette.buhl@bavarian-nordic.com 
or
Michael Becker 
MD Becker Partners 
michael@mdbpartners.com 

Get more information
Article originally appeared on Daily Dose Equities - Wall Street Analysis for Biomedical Research (http://dailydoseequities.filmannex.com/).
See website for complete article licensing information.